Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Nektar Therapeutics

10/03/2025 20:28

Nektar Therapeutics NKTR.OQ NKTR.O is expected to show a rise in quarterly revenue when it reports  results on March 12 for the period ending December 31 2024

The San Francisco California-based  company is expected to report a 25.0% increase in revenue to $29.86 million from $23.89 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Nektar Therapeutics is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Nektar Therapeutics is $4.00​, above​ its last closing price of $0.88. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.22
-0.21
-0.18
Beat
14.6
Jun. 30 2024
-0.21
-0.20
-0.25
Missed
-22.8
Mar. 31 2024
-0.19
-0.19
-0.19
Met
0​
Dec. 31 2023
-0.22
-0.21
-0.22
Missed
-3.6
​​Sep. 30 2023
-0.21
-0.20
-0.24
Missed
-20.3
Jun. 30 2023
-0.31
-0.28
-0.27
Beat
4.9​
Mar. 31 2023
-0.23
-0.25
-0.32
Missed
-26.7
Dec. 31 2022
-0.44
-0.45
-0.32
Beat
29.3

This summary was machine generated March 10 at 20:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)